Cargando…
25 Years Old Women With Inflammatory Low Back Pain
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological type of malignant lymphomas (approximately 30% of cases). DLBCL is highly curable through chemotherapy. Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AVICENA, d.o.o., Sarajevo
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010057/ https://www.ncbi.nlm.nih.gov/pubmed/27594751 http://dx.doi.org/10.5455/medarh.2016.70.219-222 |
_version_ | 1782451620436508672 |
---|---|
author | Soltani, Zahra Davatchi, Fereydon |
author_facet | Soltani, Zahra Davatchi, Fereydon |
author_sort | Soltani, Zahra |
collection | PubMed |
description | INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological type of malignant lymphomas (approximately 30% of cases). DLBCL is highly curable through chemotherapy. Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy as the most frequent of care for first - DLBCL therapy, improves long-term survival of patients effectively. CASE REPORT: A young female (25 years old) complained about pain in her right back for two years. She was suffering from backache with priority in the right and contracture in mornings. Sacroiliac joint seemed normal but lytic and sclerotic lesions and also density changing of L5 and humerus head was revealed by CT scan. Biopsy was taken from the iliac bone and diffuse large B cell lymphoma was diagnosed. CONCLUSION: Chronic pains especially in axial skeleton, pelvis area and main joints must be taken seriously and examined by CT scan and MRI. If no particular issue was reported primarily while the pain was remained, a complete diagnosis BMB associated with PET must be applied. Despite of dependency on diagnosis the treatment by CHOP in association with rituximab is the most recommended chemotherapy alternative for patients with DLBCL. |
format | Online Article Text |
id | pubmed-5010057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | AVICENA, d.o.o., Sarajevo |
record_format | MEDLINE/PubMed |
spelling | pubmed-50100572016-09-02 25 Years Old Women With Inflammatory Low Back Pain Soltani, Zahra Davatchi, Fereydon Med Arch Case Report INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological type of malignant lymphomas (approximately 30% of cases). DLBCL is highly curable through chemotherapy. Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy as the most frequent of care for first - DLBCL therapy, improves long-term survival of patients effectively. CASE REPORT: A young female (25 years old) complained about pain in her right back for two years. She was suffering from backache with priority in the right and contracture in mornings. Sacroiliac joint seemed normal but lytic and sclerotic lesions and also density changing of L5 and humerus head was revealed by CT scan. Biopsy was taken from the iliac bone and diffuse large B cell lymphoma was diagnosed. CONCLUSION: Chronic pains especially in axial skeleton, pelvis area and main joints must be taken seriously and examined by CT scan and MRI. If no particular issue was reported primarily while the pain was remained, a complete diagnosis BMB associated with PET must be applied. Despite of dependency on diagnosis the treatment by CHOP in association with rituximab is the most recommended chemotherapy alternative for patients with DLBCL. AVICENA, d.o.o., Sarajevo 2016-06 2016-05-31 /pmc/articles/PMC5010057/ /pubmed/27594751 http://dx.doi.org/10.5455/medarh.2016.70.219-222 Text en Copyright: © 2016 Zahra Soltani and Fereydoun Davatchi http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Soltani, Zahra Davatchi, Fereydon 25 Years Old Women With Inflammatory Low Back Pain |
title | 25 Years Old Women With Inflammatory Low Back Pain |
title_full | 25 Years Old Women With Inflammatory Low Back Pain |
title_fullStr | 25 Years Old Women With Inflammatory Low Back Pain |
title_full_unstemmed | 25 Years Old Women With Inflammatory Low Back Pain |
title_short | 25 Years Old Women With Inflammatory Low Back Pain |
title_sort | 25 years old women with inflammatory low back pain |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010057/ https://www.ncbi.nlm.nih.gov/pubmed/27594751 http://dx.doi.org/10.5455/medarh.2016.70.219-222 |
work_keys_str_mv | AT soltanizahra 25yearsoldwomenwithinflammatorylowbackpain AT davatchifereydon 25yearsoldwomenwithinflammatorylowbackpain |